{"created":"2023-07-25T08:14:35.723949+00:00","id":15674,"links":{},"metadata":{"_buckets":{"deposit":"ea928744-8baa-4fec-b31f-f220dcf94281"},"_deposit":{"created_by":18,"id":"15674","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"15674"},"status":"published"},"_oai":{"id":"oai:ir.kagoshima-u.ac.jp:00015674","sets":["228:230:5999","57:58:59"]},"author_link":["138480","138481","138482"],"item_7_biblio_info_5":{"attribute_name":"収録雑誌名","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"15","bibliographicPageStart":"10","bibliographicVolumeNumber":"73","bibliographic_titles":[{"bibliographic_title":"鹿児島大学医学雑誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Medical journal of Kagoshima University","bibliographic_titleLang":"en"}]}]},"item_7_date_6":{"attribute_name":"作成日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2021-02","subitem_date_issued_type":"Issued"}]},"item_7_description_4":{"attribute_name":"要約(Abstract)","attribute_value_mlt":[{"subitem_description":"A 68-year-old woman developed pain in the left lateral region of her abdomen, and three days later, rashes appeared at the T11 level on her left side (day 0). On day 9 after the onset of rash, she consulted a primary doctor and was given loxoprofen. Subsequently, she visited our hospital because of severe persistent pain on day 12 and was administered 150-300 mg/day of pregabalin, which was given from day 12 to day 43. Her platelet count continued to decrease from 18.1x104/μL to 8.8x104/μL under 100-300 mg/day of pregabalin. Reducing the dose of pregabalin to 50 mg seemed to increase the platelet count to 10.9x104/μL on days 40-43. On day 43, pregabalin was switched to 10 mg/day of mirogabalin. Although we initiated mirogabalin, the platelet count was further reduced to 6.5x104/μL on the fifth day of treatment. After mirogabalin was discontinued, the platelet count started to recover rapidly up to 17.2x104/μL until day 63. During this course of treatment, 0.2% ropivacaine was administered through an epidural catheter from day 20 to day 60, 20 mg/day of duloxetine was also given, and 200 mg/day of carbamazepine was continued throughout from day 28 and from day 37. The alteration in the patient’s platelet count seemed to be unrelated to epidural analgesia, duloxetine, and carbamazepine because the platelet count recovered to normal levels without discontinuing these drugs. In summary, we herein report a case of thrombocytopenia caused by pregabalin and possibly mirogabalin.","subitem_description_language":"en","subitem_description_type":"Other"},{"subitem_description":"症例は，68才女性．左側腹部に疼痛出現し，その3日後，左Th11の帯状疱疹が出現（day 0）．近医を受診，鎮痛剤の投与を受けた．疼痛が増悪するため，皮疹発現後12日目（day 12），当院を受診．プレガバリン内服を開始，入院治療となった．プレガバリンは投与量50~300mg/日でday43まで投与された．初診時は18.1X104/μLであった血小板は，プレガバリン投与中は減少していき8.8X104/μLまで低下をみた．プレガバリンを300mg/日から150mg/日（day 22），100mg/日（day 32），50mg/日（day 41）と減量するにつれ血小板は10.9X104/μLまで回復をみた．Day 43で投与量50mg/日であったプレガバリンは中止しミロガバリン10mg/日を開始したが，ミロガバリン投与５日目（day 50）の血小板数は6.5X104/μLまで減少していた．すぐにミロガバリンを中止したところ，中止３日後には，血小板数は7.5X104/μLと回復し始め，以後，漸次増加をみた．ミロガバリン中止後１６日目（day 63）には血小板数は，17.2X104/μLと正常範囲に達した．入院中はday 20 ～ day 60の間，0.2％ロピバカイン持続投与による持続硬膜外ブロック.0を併用した．また，day 20よりデュロキセチン20 mg/日を，day 28よりカルバマゼピン200ｍｇ/日を開始し継続した．持続硬膜外ブロック，デュロキセチン，カルバマゼピンは同量が投与継続されたままであり減量することなく血小板数の正常範囲内への回復がみられことから，血小板減少に対して硬膜外ブロックやこれらの薬剤の関与はなかったと判断した．プレガバリン，ミロガバリン投与によって血小板減少がみられ，両者の中止によって速やかに改善したことにより，今回の症例において，血小板減少はプレガバリンによって引き起こされた可能性があり，おそらくミロガバリンも関与していたと考えられる．","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_7_publisher_23":{"attribute_name":"公開者・出版者","attribute_value_mlt":[{"subitem_publisher":"鹿児島大学","subitem_publisher_language":"ja"},{"subitem_publisher":"Kagoshima University","subitem_publisher_language":"en"}]},"item_7_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03685063","subitem_source_identifier_type":"PISSN"}]},"item_7_source_id_9":{"attribute_name":"NII書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AN00040104","subitem_source_identifier_type":"NCID"}]},"item_7_subject_15":{"attribute_name":"NDC","attribute_value_mlt":[{"subitem_subject":"490","subitem_subject_scheme":"NDC"}]},"item_7_version_type_14":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KAWANO, Keiko","creatorNameLang":"en"},{"creatorName":"河野, 恵子","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"138480","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"KAMINOSONO, Tatsuya","creatorNameLang":"en"},{"creatorName":"上之薗, 達也","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"138481","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"NAGANO, Masayuki","creatorNameLang":"en"},{"creatorName":"長野, 真行","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"138482","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-03-11"}],"displaytype":"detail","filename":"AN00040104_73_p10-15.pdf","filesize":[{"value":"248.4 kB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"AN00040104_73_p10-15","objectType":"fulltext","url":"https://ir.kagoshima-u.ac.jp/record/15674/files/AN00040104_73_p10-15.pdf"},"version_id":"a7108e4a-2ae3-42a0-8a05-e6501908c53b"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Pregabalin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Mirogabalin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"adverse drug effect","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"thrombocytopenia","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"herpes zoster","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Thrombocytopenia Caused by Pregabalin and Possibly Mirogabalin Administered for Herpes Zoster Pain: A Case Report","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Thrombocytopenia Caused by Pregabalin and Possibly Mirogabalin Administered for Herpes Zoster Pain: A Case Report","subitem_title_language":"en"},{"subitem_title":"帯状疱疹神経痛患者へのプレガバリンとおそらくはミロガバリン投与によって引き起こされた血小板減少の一症例","subitem_title_language":"ja"}]},"item_type_id":"7","owner":"18","path":["59","5999"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-03-11"},"publish_date":"2021-03-11","publish_status":"0","recid":"15674","relation_version_is_last":true,"title":["Thrombocytopenia Caused by Pregabalin and Possibly Mirogabalin Administered for Herpes Zoster Pain: A Case Report"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2024-05-27T05:39:43.905615+00:00"}